Sterility Clinical Trial
Official title:
Benefits of Hysteroscopy Prior to Performing a Cycle of in Vitro Fertilization/Intracytoplasmic Sperm Injection
Verified date | May 2017 |
Source | Instituto de Investigación Hospital Universitario La Paz |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a prospective randomized open-label trial. Women scheduled for their first or second in-vitro fertilization/intracytoplasmatic Sperm Injection (IVF/ICSI) cycle and with no abnormality detected in transvaginal ultrasound examination, were randomized to two groups. In the first group (group I) 31 patients underwent hysteroscopy examination before IVF cycle while in the second group (group II) 37 patients underwent direct cycle without previous hysteroscopy
Status | Completed |
Enrollment | 75 |
Est. completion date | January 2017 |
Est. primary completion date | January 2017 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years to 40 Years |
Eligibility |
Inclusion Criteria: - Women with infertility / primary infertility. - Women who are about to start an IVF/ICSI cycle with their own eggs. - Age greater than or equal to 18 years and less than or equal to 40 years. - Women in whom a multiple follicular development will be developed with a short protocol with antagonists or long with agonists, and starting dose of gonadotropins according to clinical criteria. - Women with uterine ultrasound without endometrial pathology Exclusion Criteria: - Ovarian reserve: Antimullerian hormone <0.5 ng / dl or Count of antral follicles <5 between both ovaries. - Myomatous uterus: presence of> 2 myomas> 4cm or that deform uterine cavity. - Uterine malformations. - Body mass index (BMI) <18 or> 30. - Polycystic ovarian syndrome: according to European Society of Human Reproduction and Embryology (ESRHE)/Rotterdam 2003 criteria. - Moderate-severe endometriosis. - Background or presence of pelvic inflammatory disease. - Hydrosalpinx not excised or occluded. - Hyperprolactinemia, defined as prolactin levels greater than 50 ng / ml. - Diagnostic history of endometrial hyperplasia. - Severe male factor: severe oligoasthenoteratozoospermia with a sperm cell count (REM) <100,000 spermatozoa / ml. - Impossibility to apply the treatments provided by the study in the terms established by the protocol. - Contraindication for the use of any of the treatments provided in the study. |
Country | Name | City | State |
---|---|---|---|
Spain | La Paz University Hospital | Madrid |
Lead Sponsor | Collaborator |
---|---|
Instituto de Investigación Hospital Universitario La Paz |
Spain,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Percentage of biochemical, clinical, on-going pregnancy and livebirth of IVF treatment | Percentage of biochemical, clinical, on-going pregnancy and livebirth of IVF treatment comparing both groups. | 12 months | |
Secondary | Percentage of endocervical canal and uterine cavity pathology and the impact of treatment of these pathologies. | Percentage of endocervical canal and uterine cavity pathology and the impact of treatment of these pathologies in the rate of pregnancy and livebirth. | 12 months | |
Secondary | Rate of hysteroscopy tolerance | The tolerance of the procedure was evaluate in the patients randomized to the group I of the study. | 1 month. | |
Secondary | Hysteroscopy complication rate. | We evaluate the complication of the hysteroscopy during and after the procedure. Includes blooding, infections, uterine perforation, etc. | 2 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01955356 -
Embryo Implantation After Induced Endometrial Injury
|
N/A | |
Completed |
NCT01330771 -
Assessment of the Therapeutic Utility of r-FSH in Association With hMG-HP
|
N/A | |
Completed |
NCT01330784 -
Assessment of the Therapeutic Utility of hMG-HP
|
N/A | |
Active, not recruiting |
NCT05079685 -
HyFoSy Versus HSG as a Diagnostic Technique for Tubal Patency.
|
||
Completed |
NCT04605003 -
Effectiveness of Nasal Endoscope Sterilization Using a Novel Rig-S™ Device
|
N/A | |
Completed |
NCT02607319 -
Low Molecular Weight Heparin to Improve Pregnancy Outcome in Patients With Recurrent Implantation Failure
|
Phase 4 | |
Completed |
NCT01331720 -
Assessment of the Effectiveness and Tolerability of Ovarian Hyperstimulation
|
N/A | |
Completed |
NCT01331733 -
Comparative Assessment of the Clinical Utility of Ovarian Stimulation With Menotropin Versus Menotropin Plus GnRH Antagonist
|
N/A | |
Not yet recruiting |
NCT02648555 -
A Lifestyle Intervention to Improve in Vitro Fertilization Results
|
N/A | |
Suspended |
NCT00749853 -
Efficacy of Ovarian Stimulation Based on FSHR Genotype Status
|
Phase 3 | |
Recruiting |
NCT03177122 -
Myo-Inositol- Based Co-treatment in Women With PCOS Undergoing Assisted Reproductive Technology
|
Phase 4 | |
Completed |
NCT03169166 -
The Use of GnRH Agonist Trigger for Final Follicle Maturation in Women Undergoing Assisted Reproductive Technologies
|
Phase 4 | |
Completed |
NCT01406964 -
Chlamidia Antibodies Test for Tubal Factor Screening
|
N/A | |
Completed |
NCT01430650 -
Endometrial Priming for Embryo Transfer
|
Phase 4 | |
Completed |
NCT03561129 -
Embryotransfer Operator and Pregnancy Rate
|
||
Recruiting |
NCT05173597 -
Real-world Evidence on Follitropin Delta Individual Dosing
|
||
Recruiting |
NCT04026282 -
To Investigate the Cumulative Live Birth Rates Using GnRH Antagonist or Agonist Protocol for COS in ART Treatment
|
N/A | |
Completed |
NCT03619707 -
Oral Versus Vaginal Progesterone in the Luteal Support in Cryo-warmed Embryo Transfer Cycles
|
Phase 4 |